{"resourceType":"ValueSet","id":"2.16.840.1.113883.3.3616.200.110.102.3056","meta":{"versionId":"5","lastUpdated":"2020-08-18T10:21:27.000-04:00"},"text":{"status":"generated","div":"<div xmlns=\"http://www.w3.org/1999/xhtml\">\n      <h2>COVID19 ICD10CM Value Set Adrenal Disorders</h2>\n      <p>This value set includes codes from the following code systems:</p>\n      <ul>\n        <li>Include these codes as defined in \n          <code>http://hl7.org/fhir/sid/icd-10-cm</code>\n          <table class=\"none\">\n            <tr>\n              <td>\n                <b>Code</b>\n              </td>\n              <td>\n                <b>Display</b>\n              </td>\n            </tr>\n            <tr>\n              <td>E24</td>\n              <td>Cushing's syndrome</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>E24.0</td>\n              <td>Pituitary-dependent Cushing's disease</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>E24.1</td>\n              <td>Nelson's syndrome</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>E24.2</td>\n              <td>Drug-induced Cushing's syndrome</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>E24.3</td>\n              <td>Ectopic ACTH syndrome</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>E24.4</td>\n              <td>Alcohol-induced pseudo-Cushing's syndrome</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>E24.8</td>\n              <td>Other Cushing's syndrome</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>E24.9</td>\n              <td>Cushing's syndrome, unspecified</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>E25</td>\n              <td>Adrenogenital disorders</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>E25.0</td>\n              <td>Congenital adrenogenital disorders associated with enzyme deficiency</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>E25.8</td>\n              <td>Other adrenogenital disorders</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>E25.9</td>\n              <td>Adrenogenital disorder, unspecified</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>E26</td>\n              <td>Hyperaldosteronism</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>E26.0</td>\n              <td>Primary hyperaldosteronism</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>E26.01</td>\n              <td>Conn's syndrome</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>E26.02</td>\n              <td>Glucocorticoid-remediable aldosteronism</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>E26.09</td>\n              <td>Other primary hyperaldosteronism</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>E26.1</td>\n              <td>Secondary hyperaldosteronism</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>E26.8</td>\n              <td>Other hyperaldosteronism</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>E26.81</td>\n              <td>Bartter's syndrome</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>E26.89</td>\n              <td>Other hyperaldosteronism</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>E26.9</td>\n              <td>Hyperaldosteronism, unspecified</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>E27</td>\n              <td>Other disorders of adrenal gland</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>E27.0</td>\n              <td>Other adrenocortical overactivity</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>E27.1</td>\n              <td>Primary adrenocortical insufficiency</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>E27.2</td>\n              <td>Addisonian crisis</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>E27.3</td>\n              <td>Drug-induced adrenocortical insufficiency</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>E27.4</td>\n              <td>Other and unspecified adrenocortical insufficiency</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>E27.40</td>\n              <td>Unspecified adrenocortical insufficiency</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>E27.49</td>\n              <td>Other adrenocortical insufficiency</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>E27.5</td>\n              <td>Adrenomedullary hyperfunction</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>E27.8</td>\n              <td>Other specified disorders of adrenal gland</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>E27.9</td>\n              <td>Disorder of adrenal gland, unspecified</td>\n              <td/>\n            </tr>\n          </table>\n        </li>\n      </ul>\n    </div>"},"url":"http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3616.200.110.102.3056","version":"20200711","name":"COVID19 ICD10CM Value Set Adrenal Disorders","status":"active","date":"2020-07-11T01:00:30-04:00","publisher":"Clinical Architecture","compose":{"include":[{"system":"http://hl7.org/fhir/sid/icd-10-cm","concept":[{"code":"E24","display":"Cushing's syndrome"},{"code":"E24.0","display":"Pituitary-dependent Cushing's disease"},{"code":"E24.1","display":"Nelson's syndrome"},{"code":"E24.2","display":"Drug-induced Cushing's syndrome"},{"code":"E24.3","display":"Ectopic ACTH syndrome"},{"code":"E24.4","display":"Alcohol-induced pseudo-Cushing's syndrome"},{"code":"E24.8","display":"Other Cushing's syndrome"},{"code":"E24.9","display":"Cushing's syndrome, unspecified"},{"code":"E25","display":"Adrenogenital disorders"},{"code":"E25.0","display":"Congenital adrenogenital disorders associated with enzyme deficiency"},{"code":"E25.8","display":"Other adrenogenital disorders"},{"code":"E25.9","display":"Adrenogenital disorder, unspecified"},{"code":"E26","display":"Hyperaldosteronism"},{"code":"E26.0","display":"Primary hyperaldosteronism"},{"code":"E26.01","display":"Conn's syndrome"},{"code":"E26.02","display":"Glucocorticoid-remediable aldosteronism"},{"code":"E26.09","display":"Other primary hyperaldosteronism"},{"code":"E26.1","display":"Secondary hyperaldosteronism"},{"code":"E26.8","display":"Other hyperaldosteronism"},{"code":"E26.81","display":"Bartter's syndrome"},{"code":"E26.89","display":"Other hyperaldosteronism"},{"code":"E26.9","display":"Hyperaldosteronism, unspecified"},{"code":"E27","display":"Other disorders of adrenal gland"},{"code":"E27.0","display":"Other adrenocortical overactivity"},{"code":"E27.1","display":"Primary adrenocortical insufficiency"},{"code":"E27.2","display":"Addisonian crisis"},{"code":"E27.3","display":"Drug-induced adrenocortical insufficiency"},{"code":"E27.4","display":"Other and unspecified adrenocortical insufficiency"},{"code":"E27.40","display":"Unspecified adrenocortical insufficiency"},{"code":"E27.49","display":"Other adrenocortical insufficiency"},{"code":"E27.5","display":"Adrenomedullary hyperfunction"},{"code":"E27.8","display":"Other specified disorders of adrenal gland"},{"code":"E27.9","display":"Disorder of adrenal gland, unspecified"}]}]}}